Radiopharm Theranostics Ltd (ASX:RAD) CEO Riccardo Canevari chats with Proactive after the company signed a milestone supply agreement for an isotope used in cancer therapy. The agreement will support the company’s RAD 602 asset, a potential first-in-class radiopharmaceutical for treating brain cancers. Canevari says the isotope could expand treatment options for patients living with cancer while giving Radiopharm a competitive advantage as it embarks on a Phase 1 clinical trial.
Radiopharm Theranostics secures pivotal isotope for cancer-targeting peptide
